Literature DB >> 19955241

Is initiation of atorvastatin for employees a good buy for employers?

Steven D Culler, William S Weintraub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19955241      PMCID： PMC2787390          DOI： 10.4065/mcp.2009.0630

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  5 in total

1.  The American Heart Association's principles for comparative effectiveness research: a policy statement from the American Heart Association.

Authors:  Raymond J Gibbons; Timothy J Gardner; Jeffrey L Anderson; Larry B Goldstein; Neil Meltzer; William S Weintraub; Clyde W Yancy
Journal:  Circulation       Date:  2009-05-11       Impact factor: 29.690

2.  Primary prevention and statins: is it just about going to class?

Authors:  Richard A Krasuski
Journal:  Mayo Clin Proc       Date:  2008-12       Impact factor: 7.616

3.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

4.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Authors:  Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

5.  Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.

Authors:  Ross J Simpson; James Signorovitch; Howard Birnbaum; Jasmina Ivanova; Cristina Connolly; Yohanne Kidolezi; Andreas Kuznik
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616
  5 in total
  1 in total

1.  The high cost of cancer drugs and what we can do about it.

Authors:  Mustaqeem Siddiqui; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.